Real‐World Survival Outcomes in EGFR‐Mutant Advanced NSCLC Treated With EGFR TKIs: Insights From a Single‐Center Clinical Data Warehouse Analysis in South Korea
Based on real-world data, first-line treatment with 3G EGFR TKIs demonstrated a significant survival benefit compared with 1G/2G EGFR TKIs.
Authors
- B KIM (ORCID: https://orcid.org/0000-0002-9446-6754)
- Sokbom Kang (ORCID: https://orcid.org/0000-0002-8428-9555)
- Iksoo Huh
- Hyeoneui Kim
Institutions
- Seoul National University (KR)
- New Generation University College (ET)
- Seoul National University Hospital (KR)
Publication Details
- Journal
- Asia-Pacific Journal of Clinical Oncology
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1111/ajco.70063
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00